Response to "Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?"

den Brok, Wendie D; Speers, Caroline H; Gondara, Lovedeep; Baxter, Emily; Tyldesley, Scott K; Lohrisch, Caroline A

den Brok, Wendie D; Speers, Caroline H; Gondara, Lovedeep; Baxter, Emily; Tyldesley, Scott K; Lohrisch, Caroline A.

Afiliação

den Brok WD; Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. wdenbrok@bccancer.bc.ca.
Speers CH; Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
Gondara L; Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
Baxter E; Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
Tyldesley SK; Department of Radiation Oncology, BC Cancer Agency, Vancouver, BC, Canada.
Lohrisch CA; Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.

Breast Cancer Res Treat ; 162(2): 397-398, 2017 04.

Article em En | MEDLINE | ID: mdl-28110478

Assuntos

Neoplasias da Mama; Recidiva Local de Neoplasia; Humanos; Prognóstico; Receptor ErbB-2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Recidiva Local de Neoplasia Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google